Key Insights

Highlights

Success Rate

91% trial completion (above average)

Published Results

32 trials with published results (22%)

Research Maturity

91 completed trials (61% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

6.1%

9 terminated out of 148 trials

Success Rate

91.0%

+4.5% vs benchmark

Late-Stage Pipeline

8%

12 trials in Phase 3/4

Results Transparency

35%

32 of 91 completed with results

Key Signals

32 with results91% success

Data Visualizations

Phase Distribution

114Total
Not Applicable (33)
Early P 1 (3)
P 1 (40)
P 2 (26)
P 3 (12)

Trial Status

Completed91
Unknown18
Recruiting13
Terminated9
Not Yet Recruiting8
Active Not Recruiting6

Trial Success Rate

91.0%

Benchmark: 86.5%

Based on 91 completed trials

Clinical Trials (148)

Showing 20 of 20 trials
NCT06551844Phase 2RecruitingPrimary

Adaptive Dengue Antiviral Platform Trial

NCT06599970Active Not RecruitingPrimary

Improving Disease Prevention Strategies by Integrating Socio-spatial Characterization of Human Mobility

NCT07543458Phase 3Not Yet RecruitingPrimary

Therapeutics for Moderate and Severe Dengue

NCT07501793Active Not RecruitingPrimary

Demographic Characteristics of TAK-003 Dengue Vaccine Recipients in Vietnam

NCT07517731Not ApplicableCompletedPrimary

Using Digital Technology for the Prevention of Aedes-Borne Diseases in Colombian Communities

NCT06006559Phase 2RecruitingPrimary

A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever

NCT06595745Not ApplicableTerminatedPrimary

Testing Combined IIT-SIT to Control Mosquito-Borne Diseases At Scale

NCT06891950Phase 3RecruitingPrimary

Butantan-DV Vaccine in Elderly Populations (DEN-04-IB)

NCT06973772Phase 3Not Yet RecruitingPrimary

Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years.

NCT07412483Not ApplicableRecruitingPrimary

A Controlled Human Infection Model of Dengue

NCT04478370Not ApplicableCompleted

Characterizing Humoral Immune Response to Mosquito Bites

NCT07358910RecruitingPrimary

Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective

NCT06837116Early Phase 1CompletedPrimary

Immunogenicity of an Intradermal Qdenga Vaccine Among Healthy Volunteers

NCT05611710Phase 2Active Not RecruitingPrimary

Anakinra in Dengue With Hyperinflammation ( AnaDen )

NCT07016321Phase 2Not Yet RecruitingPrimary

Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative)

NCT03612609Not ApplicableCompletedPrimary

Pilot Study to Detect DENGUE Virus in Sperm

NCT05710224Phase 2CompletedPrimary

Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181 - 002)

NCT06528457Phase 2CompletedPrimary

Study to Examine the Effects of Oral Fenretinide

NCT07203183Not Yet RecruitingPrimary

Dengue - Sample Collection Study Pakistan

NCT04343521Not ApplicableCompleted

Quantifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases

Scroll to load more

Research Network

Activity Timeline